Cargando…
Measuring the cost-effectiveness of treatments for people with multiple sclerosis: Beyond quality-adjusted life-years
BACKGROUND: It is a familiar story. A promising multiple sclerosis (MS) treatment clears the three regulatory hurdles of safety, quality and efficacy, only to fall at the fourth: cost-effectiveness. This has led to concerns about the validity of the measures typically used to quantify treatment effe...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
SAGE Publications
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894952/ https://www.ncbi.nlm.nih.gov/pubmed/32880511 http://dx.doi.org/10.1177/1352458520954172 |